Show simple item record

dc.contributor.authorHomicsko, K
dc.contributor.authorDummer, R
dc.contributor.authorHoeller, C
dc.contributor.authorWolchok, JD
dc.contributor.authorHodi, FS
dc.contributor.authorLarkin, J
dc.contributor.authorAscierto, PA
dc.contributor.authorAtkinson, V
dc.contributor.authorRobert, C
dc.contributor.authorPostow, MA
dc.contributor.authorRe, S
dc.contributor.authorPaulucci, D
dc.contributor.authorDobler, D
dc.contributor.authorMichielin, O
dc.coverage.spatialSwitzerland
dc.date.accessioned2022-08-26T10:54:52Z
dc.date.available2022-08-26T10:54:52Z
dc.date.issued2022-05-05
dc.identifierARTN 2300
dc.identifiercancers14092300
dc.identifier.citationCancers, 2022, 14 (9), pp. 2300 -en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5335
dc.identifier.eissn2072-6694
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers14092300
dc.description.abstractThe impact of proton pump inhibitors (PPIs) on clinical outcomes with first-line immune checkpoint inhibitors (ICIs) in patients with metastatic melanoma was previously analyzed in the phase II study, CheckMate 069. This retrospective analysis utilized data from three phase II/III studies of first-line ICI therapy in untreated advanced melanoma: CheckMate 066, 067, and 069. All randomized patients with PPI use ≤ 30 days before initiating study treatment were included in the PPI-use subgroup. Possible associations between baseline PPI use and efficacy were evaluated within each treatment arm of each study using multivariable modeling. Approximately 20% of 1505 randomized patients across the studies reported baseline PPI use. The median follow-up was 52.6-58.5 months. Objective response rate (ORR), progression-free survival (PFS), and overall survival analyses provided insufficient evidence of a meaningful association between PPI use and efficacy outcomes with nivolumab-plus-ipilimumab, nivolumab, or ipilimumab therapy. In five of the six ICI treatment arms, 95% confidence intervals for odds ratios or hazard ratios traversed 1. Significant associations were observed in the CheckMate 069 combination arm between PPI use and poorer ORR and PFS. This multivariable analysis found insufficient evidence to support meaningful associations between PPI use and ICI efficacy in patients with advanced melanoma.
dc.formatElectronic
dc.format.extent2300 -
dc.languageeng
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofCancers
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectcheckpoint inhibitors
dc.subjectmelanoma
dc.subjectpooled analysis
dc.subjectproton pump inhibitors
dc.titleProton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-04-25
dc.date.updated2022-08-26T10:54:17Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cancers14092300en_US
rioxxterms.licenseref.startdate2022-05-05
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35565428
pubs.issue9
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.publication-statusPublished online
pubs.volume14
dc.contributor.icrauthorLarkin, James
icr.provenanceDeposited by Mr Arek Surman (impersonating Prof James Larkin) on 2022-08-26. Deposit type is initial. No. of files: 1. Files: Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/